GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Piotroski F-Score

Vericel (Vericel) Piotroski F-Score : 5 (As of Apr. 25, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vericel has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Vericel's Piotroski F-Score or its related term are showing as below:

VCEL' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 5

During the past 13 years, the highest Piotroski F-Score of Vericel was 6. The lowest was 2. And the median was 4.


Vericel Piotroski F-Score Historical Data

The historical data trend for Vericel's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Piotroski F-Score Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 6.00 3.00 5.00

Vericel Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 5.00 5.00 5.00

Competitive Comparison of Vericel's Piotroski F-Score

For the Biotechnology subindustry, Vericel's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Vericel's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -7.495 + -5.02 + -3.66 + 12.993 = $-3.2 Mil.
Cash Flow from Operations was 7.86 + 10.196 + 7.169 + 10.086 = $35.3 Mil.
Revenue was 41.017 + 45.922 + 45.581 + 64.996 = $197.5 Mil.
Gross Profit was 26.52 + 29.941 + 30.608 + 48.507 = $135.6 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(273.003 + 265.096 + 310.711 + 318.125 + 353.657) / 5 = $304.1184 Mil.
Total Assets at the begining of this year (Dec22) was $273.0 Mil.
Long-Term Debt & Capital Lease Obligation was $81.9 Mil.
Total Current Assets was $205.6 Mil.
Total Current Liabilities was $45.7 Mil.
Net Income was -7.091 + -8.963 + -6.577 + 5.922 = $-16.7 Mil.

Revenue was 36.074 + 37.046 + 38.551 + 52.694 = $164.4 Mil.
Gross Profit was 23.452 + 22.854 + 25.233 + 38.249 = $109.8 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(243.705 + 240.288 + 244.815 + 248.017 + 273.003) / 5 = $249.9656 Mil.
Total Assets at the begining of last year (Dec21) was $243.7 Mil.
Long-Term Debt & Capital Lease Obligation was $43.3 Mil.
Total Current Assets was $186.9 Mil.
Total Current Liabilities was $37.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vericel's current Net Income (TTM) was -3.2. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Vericel's current Cash Flow from Operations (TTM) was 35.3. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-3.182/273.003
=-0.01165555

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-16.709/243.705
=-0.0685624

Vericel's return on assets of this year was -0.01165555. Vericel's return on assets of last year was -0.0685624. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Vericel's current Net Income (TTM) was -3.2. Vericel's current Cash Flow from Operations (TTM) was 35.3. ==> 35.3 > -3.2 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=81.856/304.1184
=0.26915833

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=43.268/249.9656
=0.17309582

Vericel's gearing of this year was 0.26915833. Vericel's gearing of last year was 0.17309582. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=205.631/45.749
=4.49476491

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=186.866/37.463
=4.98801484

Vericel's current ratio of this year was 4.49476491. Vericel's current ratio of last year was 4.98801484. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Vericel's number of shares in issue this year was 47.749. Vericel's number of shares in issue last year was 47.232. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=135.576/197.516
=0.68640515

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=109.788/164.365
=0.66795242

Vericel's gross margin of this year was 0.68640515. Vericel's gross margin of last year was 0.66795242. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=197.516/273.003
=0.72349388

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=164.365/243.705
=0.67444246

Vericel's asset turnover of this year was 0.72349388. Vericel's asset turnover of last year was 0.67444246. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Vericel has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Vericel  (NAS:VCEL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Vericel Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Vericel's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel (Vericel) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019